Table 1.
Patient characteristics and univariable analysis of overall survival and overall recurrence
| Overall Survival (n = 1387) | Overall Recurrence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||
| N | HR 95%CI | P value | HR 95%CI | P value | 5-yr CIR | SHR 95% CI | P value | SHR 95% CI | P value | |
| Primary tumor factor | ||||||||||
| Age at surgery, years | ||||||||||
| ≤ 65 | 971 | 1 | 1 | 19.9% | 1 | |||||
| >65 | 416 | 1.169(1.010–1.352) | 0.036 | 1.112(0.898–1.376) | 0.330 | 21.0% | 1.063(0.826–1.368) | 0.633 | ||
| Sex | ||||||||||
| Male | 772 | 1 | 21.7% | 1 | ||||||
| Female | 615 | 0.965(0.930–1.220) | 0.364 | 18.3% | 0.821(0.647–1.041) | 0.104 | ||||
| Smoking history | ||||||||||
| Never | 783 | 1 | 1 | 18.9% | 1 | |||||
| Ever | 604 | 0.875(0.762–1.004) | 0.057 | 1.152(1.026–1.432) | 0.043 | 21.9% | 1.192(0.944–1.506) | 0.105 | ||
| Pathologic stage | ||||||||||
| IA | 488 | 1 | 1 | 12.8% | 1 | 1 | ||||
| IB | 899 | 1.217(1.106–1.461) | 0.001 | 1.318(1.071–1.621) | 0.010 | 24.2% | 2.048(1.547–2.710) | < 0.001 | 1.123(0.633–1.994) | 0.692 |
| Surgery | ||||||||||
| Lobectomy | 1223 | 1 | 1 | 20.6% | 1 | |||||
| Sublobar | 164 | 1.548(1.280–1.871) | < 0.001 | 1.196(0.914–1.564) | 0.192 | 20.7% | 1.053(0.590–1.274) | 0.468 | ||
| Tumor histology | ||||||||||
| LUAD | 1028 | 1 | 19.1% | 1 | ||||||
| LUSC | 276 | 0.693(0.576–0.835) | 22.3% | 1.198(0.901–1.593) | ||||||
| LASC | 49 | 0.775(0.520–1.155) | 30.6% | 1.757(1.040–2.970) | ||||||
| Others | 34 | 1.081(0.700–1.669) | 0.001 | 20.6% | 1.115(0.525–2.369) | 0.145 | ||||
| Carcinoma type | ||||||||||
| LUAD | 1028 | 1 | 1 | 19.1% | 1 | 1 | ||||
| Non-Non-LUAD | 359 | 0.735(0.623–0.867) | < 0.001 | 1.041(0.140–1.733) | 0.929 | 23.3% | 1.262(0.978–1.629) | 0.074 | 1.987(0.837–2.344) | 0.073 |
| Predominant subtype of LUAD | ||||||||||
| MIA | 12 | 1 | 1 | 8.3% | 1 | 1 | ||||
| Lepidic | 183 | 0.580(0.322–0.994) | 1.446(0.587–3.562) | 10.9% | 1.293(0.174–9.636) | 0.961(0.127–1.261) | ||||
| Acinar | 178 | 1.084(0.603–1.950) | 1.119(0.615–2.035) | 20.7% | 2.603(0.357–8.974) | 1.833(0.247–3.623) | ||||
| Papillary | 48 | 0.877(0.464–1.659) | 1.487(0.574–3.856) | 25.0% | 3.178(0.413–4.443) | 1.984(0.251–5.702) | ||||
| Micropapillary | 2 | 0.478(0.107–2.137) | 0.807(0.800–6.262) | 50.0% | 10.576(0.661–16.154) | 9.424(0.559–10.928) | ||||
| Solid | 24 | 1.501(0.746–3.023) | < 0.001 | 1.611(0.786–3.300) | < 0.001 | 33.4% | 4.911(0.614–9.268) | 0.070 | 2.979(0.368–4.104) | 0.030 |
| EGFR status | ||||||||||
| Wild-type | 206 | 1 | 33.0% | 1 | ||||||
| Mutated | 277 | 1.032(0.849–1.255) | 0.753 | 27.0% | 0.789(0.568–1.095) | 0.157 | ||||
| LVI | ||||||||||
| Absent | 1336 | 1 | 1 | 19.0% | 1 | 1 | ||||
| Present | 51 | 1.414(1.013–1.975) | 0.042 | 1.086(0.601–1.996) | 0.790 | 51.0% | 3.364(2.247–5.038) | < 0.001 | 1.586(1.339–2.936) | 0.037 |
| VPI | ||||||||||
| Absent | 818 | 1 | 15.9% | 1 | 1 | |||||
| Present | 569 | 0.899(0.783–1.033) | 0.132 | 26.4% | 1.779(1.408–2.248) | < 0.001 | 1.217(1.073–1.833) | 0.006 | ||
| Adjuvant chemotherapy (stage IB) | 899 | |||||||||
| No Chemotherapy | 555 | 1 | 13.5% | 1 | 1 | |||||
| Chemotherapy | 344 | 1.038(0.870–1.238) | 0.678 | 41.3% | 3.925(2.952–5.219) | < 0.001 | 4.433(2.736–7.813) | < 0.001 | ||
Abbreviations: CIR cumulative incidence of recurrence, AIS adenocarcinoma in situ, MIA minimally invasive adenocarcinoma, LVI lymphovascular invasion, VPI visceral pleural invasion, LUAD lung adenocarcinoma, LUSC lung squamous carcinoma, LASC lung adenosquamous carcinoma, NSCLC non-small-cell lung cancer